DaunoXome liposomal daunorubicin data

Data on DaunoXome for the treatment of AIDS-related (KS) were presented in four sessions at the NCI-EORTC Symposium on New Drugs in Cancer Therapy in Amsterdam.

In a Phase II trial in 35 patients with pulmonary KS, 15 (43 percent) showed complete or partial resolution of symptoms. Patients received 60 mg/m2 iv of the drug every two weeks. Side effects included fever (57 percent), nausea (53 percent), fatigue (43 percent), vomiting (40 percent), neutropenia (40 percent) and elevated levels of bilirubin (6 percent). ...